Comparison of Investigator-Reported and Clinical Event Committee-Adjudicated Outcome Events in GLASSY.

benchmarking feasibility studies hemorrhage myocardial infarction thrombosis

Journal

Circulation. Cardiovascular quality and outcomes
ISSN: 1941-7705
Titre abrégé: Circ Cardiovasc Qual Outcomes
Pays: United States
ID NLM: 101489148

Informations de publication

Date de publication:
02 2021
Historique:
pubmed: 5 2 2021
medline: 28 9 2021
entrez: 4 2 2021
Statut: ppublish

Résumé

Event adjudication by a clinical event committee (CEC) provides a standardized, independent outcome assessment. However, the added value of CEC to investigators reporting remains debated. GLASSY (GLOBAL LEADERS Adjudication Sub-Study) implemented, in a subset of the open-label, investigator-reported (IR) GLOBAL LEADERS trial, an independent adjudication process of reported and unreported potential outcome events (triggers). We describe metrics of GLASSY feasibility and efficiency, diagnostic accuracy of IR events, and their concordance with corresponding CEC-adjudicated events. We report the proportion of myocardial infarction, bleeding, stroke, and stent thrombosis triggers with sufficient evidence for assessment (feasibility) that were adjudicated as outcome events (efficiency), stratified by source (IR or non-IR). Using CEC-adjudicated events as criterion standard, we describe sensitivity, specificity, positive and negative predictive value, and global diagnostic accuracy of IR events. Using Gwet AC coefficient, we examine the concordance between IR- and corresponding CEC-adjudicated triggers. There was sufficient evidence for assessment for 2592 (98.3%) of 2636 triggers. Overall, the adjudicated end point-to-trigger ratio was high and similar between IR- (88%) and non-IR-reported (87%) triggers. The global diagnostic accuracy and concordance between IR-reported and CEC-adjudicated outcome events was 0.70 (95% CI, 0.65-0.74) and 0.54 (95% CI, 0.45-0.62), respectively, for myocardial infarction; 0.77 (95% CI, 0.75-0.79) and 0.71 (95% CI, 0.68-0.74) for bleeding; 0.70 (95% CI, 0.62-0.79) and 0.59 (95% CI, 0.43-0.74) for stroke; 0.59 (95% CI, 0.52-0.66) and 0.39 (95% CI, 0.25-0.53) for stent thrombosis. For IR bleedings, the concordance with the CEC on type of events was generally weak. Implementing CEC adjudication in a pragmatic open-label trial with IR events is feasible and efficient. Our findings of modest global diagnostic accuracy for IR events and generally weak concordance between investigators and CEC support the role for CEC adjudication in such settings. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03231059.

Sections du résumé

BACKGROUND
Event adjudication by a clinical event committee (CEC) provides a standardized, independent outcome assessment. However, the added value of CEC to investigators reporting remains debated. GLASSY (GLOBAL LEADERS Adjudication Sub-Study) implemented, in a subset of the open-label, investigator-reported (IR) GLOBAL LEADERS trial, an independent adjudication process of reported and unreported potential outcome events (triggers). We describe metrics of GLASSY feasibility and efficiency, diagnostic accuracy of IR events, and their concordance with corresponding CEC-adjudicated events.
METHODS
We report the proportion of myocardial infarction, bleeding, stroke, and stent thrombosis triggers with sufficient evidence for assessment (feasibility) that were adjudicated as outcome events (efficiency), stratified by source (IR or non-IR). Using CEC-adjudicated events as criterion standard, we describe sensitivity, specificity, positive and negative predictive value, and global diagnostic accuracy of IR events. Using Gwet AC coefficient, we examine the concordance between IR- and corresponding CEC-adjudicated triggers. There was sufficient evidence for assessment for 2592 (98.3%) of 2636 triggers.
RESULTS
Overall, the adjudicated end point-to-trigger ratio was high and similar between IR- (88%) and non-IR-reported (87%) triggers. The global diagnostic accuracy and concordance between IR-reported and CEC-adjudicated outcome events was 0.70 (95% CI, 0.65-0.74) and 0.54 (95% CI, 0.45-0.62), respectively, for myocardial infarction; 0.77 (95% CI, 0.75-0.79) and 0.71 (95% CI, 0.68-0.74) for bleeding; 0.70 (95% CI, 0.62-0.79) and 0.59 (95% CI, 0.43-0.74) for stroke; 0.59 (95% CI, 0.52-0.66) and 0.39 (95% CI, 0.25-0.53) for stent thrombosis. For IR bleedings, the concordance with the CEC on type of events was generally weak.
CONCLUSIONS
Implementing CEC adjudication in a pragmatic open-label trial with IR events is feasible and efficient. Our findings of modest global diagnostic accuracy for IR events and generally weak concordance between investigators and CEC support the role for CEC adjudication in such settings. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03231059.

Identifiants

pubmed: 33535773
doi: 10.1161/CIRCOUTCOMES.120.006581
doi:

Banques de données

ClinicalTrials.gov
['NCT03231059']

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e006581

Commentaires et corrections

Type : CommentIn

Auteurs

Sergio Leonardi (S)

Department of Molecular Medicine, Cardiology Unit, University of Pavia, Italy (S.L.).
Coronary Care Unit (S.L.), Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy.

Mattia Branca (M)

Clinical Trials Unit Bern (M.B.), University of Bern, Switzerland.

Anna Franzone (A)

Department of Advanced Biomedical Sciences, Federico II University of Naples, Italy (A.F., R.P.).

Eugene McFadden (E)

Cardialysis Core Laboratories and Clinical Trial Management, Rotterdam, the Netherlands (E.M.).
Department of Cardiology, Cork University Hospital, Ireland (E.M.).

Raffaele Piccolo (R)

Department of Advanced Biomedical Sciences, Federico II University of Naples, Italy (A.F., R.P.).

Peter Jüni (P)

Department of Medicine, Applied Health Research Centre, Li Ka Shing Knowledge Institute of St. Michael's Hospital, University of Toronto, Ontario, Canada (P.J.).

Pascal Vranckx (P)

Department of Cardiology and Critical Care Medicine, Hartcentrum Hasselt, Jessa Ziekenhuis, Belgium (P.V.).

Philippe Gabriel Steg (PG)

Hôpital Bichat, AP-HP, Université Paris-Diderot, France (P.G.S.).

Patrick W Serruys (PW)

Department of Cardiology, Imperial College of London, United Kingdom (P.W.S.).

Edouard Benit (E)

Department of Cardiology, Jessa Hospital, Hasselt, Belgium (E.B.).

Christoph Liebetrau (C)

Department of Cardiology, Kerckhoff Heart and Thorax Center, Bad Nauheim, Germany (C.L., C.H.).

Luc Janssens (L)

German Center for Cardiovascular Research, Partner Site RheinMain, Frankfurt am Main, Germany (C.L., C.H.).

Maurizio Ferrario (M)

Division of Cardiology (M.F.), Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy.

Aleksander Zurakowski (A)

Department of Interventional Cardiology, American Heart of Poland SA, Chrzanów (A.Z.).

Roberto Diletti (R)

Thoraxcenter, Erasmus Medical Center, Rotterdam, the Netherlands (R.D.).

Marcello Dominici (M)

Santa Maria University Hospital, Terni, Italy (M.D.).

Kurt Huber (K)

3rd Medical Department, Cardiology, Wilhelminen Hospital, Vienna, Austria (K.H.).

Ton Slagboom (T)

Sigmund Freud University Medical School, Vienna, Austria (K.H.).

Pawel Buszman (P)

Center for Cardiovascular Research and Development, American Heart of Poland, Ustroń (P.B.).
Department of Epidemiology and Statistics, Medical University of Silesia, Katowice, Poland (P.B.).

Leonardo Bolognese (L)

Azienda Toscana Usl Sudest, Arezzo, Italy (L.B.).

Carlo Tumscitz (C)

Cardiology Unit Sant'Anna Hospital, Ferrara, Italy (C.T.).

Krzysztof Bryniarski (K)

Jagiellonian University Medical College, John Paul II Hospital, Krakow, Poland (K.B.).

Adel Aminian (A)

Department of Cardiology, Centre Hospitalier Universitaire de Charleroi, Belgium (A.A.).

Mathias Vrolix (M)

Ziekenhuis Oost Limburg, Genk, Belgium (M. Vrolix).

Ivo Petrov (I)

Acibadem City Clinic Cardiovascular Center, Sofia, Bulgaria (I.P.).

Scot Garg (S)

East Lancashire Hospitals NHS Trust, Blackburn, United Kingdom (S.G.).

Cristoph Naber (C)

Contilia Heart and Vascular Centre, Stadtspital Triemli, Zürich, Switzerland (C.N.).

Janusz Prokopczuk (J)

Polsko-Amerykańskie Kliniki Serca Kozle, Poland (J.P.).

Christian Hamm (C)

Department of Cardiology, Kerckhoff Heart and Thorax Center, Bad Nauheim, Germany (C.L., C.H.).
German Center for Cardiovascular Research, Partner Site RheinMain, Frankfurt am Main, Germany (C.L., C.H.).

Dik Heg (D)

Institute of Social and Preventive Medicine and Clinical Trials Unit (D.H.), University of Bern, Switzerland.

Stephan Windecker (S)

Department of Cardiology, Inselspital (S.W.), University of Bern, Switzerland.

Marco Valgimigli (M)

Department of Cardiology, Cardiocentro Ticino, Lugano, Switzerland (M. Valgimigli).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH